FRMD6-AS2

Across TCGA pan-cancer cohorts, FRMD6-AS2 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated FRMD6-AS2 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FRMD6-AS2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated FRMD6-AS2 expression acts as an unfavorable survival marker, although some lineages such as CHOL and ESCA show a favorable association.

LIHC, THCA, and ACC are the cancer types where FRMD6-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	III,IV	0.280	0.750	.002	81	view →
THCA	DFS	Tertile	II,III,IV	0.355	0.769	<.001	51	view →
ACC	DFS	Tertile	All	0.114	0.595	<.001	48	view →
CHOL	DFS	Tertile	II,III,IV	0.806	0.119	.011	46	view →
BLCA	OS	Quartile	All	0.499	0.669	.010	44	view →
HNSC	DFS	Tertile	All	0.268	0.418	.014	38	view →
KIRC	DFS	Quartile	III,IV	0.306	0.520	.003	24	view →
ESCA	OS	Median	All	0.609	0.410	.001	24	view →
KIRP	OS	Tertile	All	0.313	0.795	<.001	24	view →
READ	OS	Tertile	III,IV	0.705	0.952	<.001	19	view →
STAD	DFS	Quartile	II,III,IV	0.551	0.769	.023	17	view →
LUSC	OS	Median	II,III,IV	0.785	0.678	.025	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

FRMD6-AS2–LIHC (OS)

Open the LIHC breakdown →